Cornelia Landersdorfer

Personal profile

Biography

Senior Lecturer - Centre for Medicine Use and Safety

NHMRC Career Development Fellowship (CDF)- Drug Delivery, Disposition and Dynamics Faculty of Pharmacy and Pharmaceutical Sciences

Research interests

Antibiotic mono- and combination therapy to achieve synergistic bacterial killing and prevent resistance Population pharmacokinetics, pharmacodynamics, and optimised dosage regimens of anti-infectives and other agents

Tissue penetration into bone and other tissues

Drug-drug interactions and their analysis by mechanism-based mathematical models

Mechanism-based population modelling of the glucose-insulin system, drug effects and disease progression in type 2 diabetes

Renal elimination mechanisms

Monash teaching commitment

Coordinating the CMUS PhD student training (CMUS masterclasses)

PSC2041 / BPS2041 Biopharmaceutics (second year Pharm Sci) - Unit coordinator and teaching pharmacokinetics

PAC3191 Microbiology and Immunology (third year Pharmacy) - Unit coordinator

PHR1022 How Medicines Work II (first year Pharmacy) - teaching pharmacokinetics, pharmacogenomics, pharmacokinetics/pharmacodynamics

PSC3212 Product Commercialistion (third year Pharm Sci) - teaching in vitro / in vivo correlation, bioavailability, bioequivalence, target effects

PhD student training in workshops on mechanism-based, population pharmacokinetic / pharmacodynamic modelling and simulation

Teaching applications of mechanism-based modelling to pharmaceutical industry

Education/Academic qualification

Pharmaceutical Sciences, PhD, University of Wuerzburg

2002 → 2006

Pharmacy and Pharmaceutical Sciences, BPharm, Universitat Regensburg (University of Regensburg)

1996 → 2001

External positions

Adjunct Assistant Professor, University at Buffalo, The State University of New York

15 Aug 2009 → …

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2022

5 Active
10 Finished

Combating Pseudomonas aeruginosa infections in paediatric patients with cystic fibrosis

Landersdorfer, C., Deveson, D., Boyce, J., Nation, R. & Oliver, A.

1/01/19 → 31/12/19

Project: Research

Overcoming multidrug-resistant hypermutable Pseudomonas aeruginosa via antibiotic combinations

Landersdorfer, C., Oliver, A., Harper, M. & Nation, R.

National Health & Medical Research Council (NHMRC)

1/01/19 → 31/12/22

Project: Research

Novel dosing regimens to maximise antibiotic effectiveness for treatment of pneumonia in the intensive care unit

Roberts, J., Lipman, J., De Waele, J., Koulenti, D. & Landersdorfer, C.

National Health & Medical Research Council (NHMRC)

1/01/19 → 31/12/22

Project: Research

Targeting hypermutable 'superbugs' in chronic respiratory infections by optimised antibiotic combination dosage regimens

Landersdorfer, C., Boyce, J., Bulitta, J., Nation, R. & Oliver, A.

National Health & Medical Research Council (NHMRC)

1/01/16 → 31/12/19

Project: Research

Centre for REdefining antibiotic use to reDUce resistanCE and prolong the lives of antibiotics (REDUCE)

Roberts, J. A., Lipman, J., Peake, S., Turnidge, J., Slavin, M., Hopkins, P. M. A., Landersdorfer, C., Paul, S. K., De Waele, J., Joynt, G. & Udy, A.

1/12/15 → 30/11/20

Project: Research

Research Output 2002 2019

85 Article
4 Letter
1 Chapter (Book)
1 Review Article

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

Rees, V. E., Deveson Lucas, D. S., López-Causapé, C., Huang, Y., Kotsimbos, T., Bulitta, J. B., Rees, M. C., Barugahare, A., Peleg, A. Y., Nation, R. L., Oliver, A., Boyce, J. D. & Landersdorfer, C. B., 1 Apr 2019, In : Antimicrobial Agents and Chemotherapy. 63, 4, 11 p., e02538-18.

Research output: Contribution to journal › Article › Research › peer-review

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis

Bulitta, J. B., Jiao, Y., Drescher, S. K., Oliver, A., Louie, A., Moya, B., Tao, X., Wittau, M., Tsuji, B. T., Zavascki, A. P., Shin, B. S., Drusano, G. L., Sörgel, F. & Landersdorfer, C. B., 6 Feb 2019, In : Clinical Pharmacokinetics. 58, 2, p. 143-156 14 p.

Research output: Contribution to journal › Article › Research › peer-review

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling

Landersdorfer, C. B., Yadav, R., Rogers, K. E., Kim, T. H., Shin, B. S., Boyce, J. D., Nation, R. L. & Bulitta, J. B., 1 Apr 2018, In : Antimicrobial Agents and Chemotherapy. 62, 4, 8 p., e02053-17.

Research output: Contribution to journal › Article › Research › peer-review

Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli

Bergen, P. J., Bulitta, J. B., Sime, F. B., Lipman, J., McGregor, M. J., Millen, N., Paterson, D. L., Kirkpatrick, C. M. J., Roberts, J. A. & Landersdorfer, C. B., 1 May 2018, In : Diagnostic Microbiology and Infectious Disease. 91, 1, p. 69-76 8 p.

Research output: Contribution to journal › Article › Research › peer-review